Tempest Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Brisbane, CA
TPST chart
What traders are saying about $TPST
Latest postsTempest Therapeutics, Inc. news
- Form DEF 14A Tempest Therapeutics For: 26 October By Investing.com
Investing.com Canada ·
- Tempest Therapeutics, Inc. Estimates – NASDAQ:TPST
TradingView ·
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga ·
- Form 8K Tempest Therapeutics Inc For: 20 October By Investing.com
Investing.com Nigeria ·
- Tempest Therapeutics adjourns special meeting, sets reconvened date for November
Investing.com ·
- Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
Yahoo Finance ·
- Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Yahoo Finance ·
- Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Yahoo Finance ·
- Tempest Therapeutics Announces Up to $7.5 Million Private Placement
Yahoo Finance ·
- Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Yahoo Finance ·
- Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Yahoo Finance ·
Tempest Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$26.3M | -$41.8M | -$29.5M | -$35.7M |
| Diluted EPS | $-6.33 | $-19.50 | $-1.91 | $-3.09 |
| Total assets (year end) | $16.9M | $41.5M | $51.6M | $46.1M |
| Cash and equivalents (year end) | $7.7M | $30.3M | $39.2M | $31.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- DEF 14ADEFINITIVE PROXY STATEMENT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-K8-K
- 8-K8-K
- 8-K8-K
- 8-K8-K
- S-1S-1
- 8-K8-K
- 10-Q10-Q
- 8-K8-K
About Tempest Therapeutics, Inc.
- Ticker
- TPST (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Brisbane, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1544227
- Former names
- Millendo Therapeutics, Inc., OvaScience, Inc.
Frequently asked questions
What exchange is Tempest Therapeutics, Inc. listed on?
Tempest Therapeutics, Inc. trades on the Nasdaq under the ticker symbol TPST.
What industry is Tempest Therapeutics, Inc. in?
Tempest Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Tempest Therapeutics, Inc. headquartered?
Tempest Therapeutics, Inc.'s business address on file with the SEC is in Brisbane, CA.
When does Tempest Therapeutics, Inc.'s fiscal year end?
Tempest Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Tempest Therapeutics, Inc. report?
Tempest Therapeutics, Inc. reported $295,000 in revenue for calendar year 2017, according to its SEC filings.